Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Defence Therapeutics Inc
DTCDefence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; and mRNA vaccination program. It also offers Accuvac for dendritic cell cancer vaccines; a protein-based vaccine formulation against COVID and infectious diseases; and cervical cancer vaccine. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Vancouver, Canada. Address: 1680 ? 200 Burrard Street, Vancouver, BC, Canada, V6C 3L6
Analytics
Precio Objetivo de WallStreet
15.33 CADRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave DTC
Análisis de dividendos DTC
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout DTC
Valoración de la acción DTC
Finanzas DTC
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |